3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Endometrial Neoplasms
10
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Pancreatic Neoplasms
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
3
Triple Negative Breast Neoplasms
2
Rectal Neoplasms
2
Lung Neoplasms
2
Locally Advanced Rectal Cancer (LARC)
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Neuroendocrine
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
1
Penile Neoplasms
1
Pathologic Complete Response
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Neoplasms, Second Primary
1
Mouth Neoplasms
1
Interventions
Cisplatin
28
Pemetrexed
24
pembrolizumab
12
Nivolumab
10
Carboplatin
9
atezolizumab
7
Gemcitabine
7
Cyclophosphamide
7
durvalumab
6
Drug Therapy
6
sodium thiosulfate
5
Radiotherapy, Intensity-Modulated
5
tremelimumab
4
aldesleukin
4
Radiotherapy
4
Interleukin-2
4
sargramostim
3
Vinorelbine
3
Platinum
3
Photochemotherapy
3
Ipilimumab
3
Doxorubicin
3
Dihematoporphyrin Ether
3
Chemotherapy, Adjuvant
3
Cerebral Decortication
3
vatalanib
2
regorafenib
2
niraparib
2
lenvatinib
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Mesothelioma, Malignant
×
dostarlimab
×
Clear all
NCT03654833
2023-03-14
MiST
University of Leicester
Phase 2
Unknown
186 enrolled